Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Tivantinib (Primary) ; Erlotinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Results (n=16) of exome sequencing of tumor samples of patients from this study, presented at the 42nd European Society for Medical Oncology Congress.
- 09 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.